Antithrombin Market Share, Insight, Report, Trends, Analysis, & Forecast

SKU: DMPH4035 | Last Updated On: Mar 28 2022 | Available Formats

> Global Antithrombin Market Expected to reach a high CAGR of 4.6% By 2029: DataM Intelligence

Antithrombin Market is segmented By Usage (Therapeutics, Diagnostics, Research, Other), By Type (Anticoagulant, Antiplatelet, Thrombolytic Drug), By Route of Administration (Oral, Parenteral), By Source (Human, Recombinant Goat milk, Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The "Global Antithrombin Market" is predicted to reach at a high CAGR of 4.6% during the forecast period (2022-2029).

Antithrombin is a protein present in blood that inhibits blood clotting by inactivating thrombin. Antithrombin is produced by liver and consists of 432 amino acids. There are two major reasons of antithrombin deficiency, which include acquired antithrombin deficiency caused due to other diseases. . If a person is suffering from antithrombin deficiency, her blood will have a tendency to clot too much in the veins, a rare condition called as thrombosis.

Source: DataM Intelligence Analysis (2020)

Market Dynamics

The global antithrombin market growth is driven by the acceptance of antithrombin in several medical conditions over conventional once is contribute to driving the demand for products which drive the global antithrombin market.

The growing incidence of disease is expected to drive the market growth in the forecast period   

The growing incidence of conditions (like sepsis, congenital antithrombin deficiency, disseminated intravascular coagulation (DIC), extracorporeal membrane oxygenation (ECMO)), are likely to increase the growth of the global antithrombin market. Thrombotic diseases require a long term treatment of antithrombin drugs, this contributes to the increase in production and sales of Antithrombin. The increased usage of rapid diagnostic tests, which in turn use antithrombin, drive the demand of the protein in the diagnostic field. Moreover, key players are investing in research and development in order to develop new therapeutics to address the unmet needs. This in turn to drive the growth of the global antithrombin market. For instance, China Biologic Products Holdings, Inc. integrated plasma-based biopharmaceutical company in China develop Human Antithrombin III for treatment of hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and thromboembolism is in clinical trial phase III. These factors are driving the growth of the market in the forecast period.

Increasing Number of Surgical Procedures, expected to drive the market growth

The global antithrombin market is poised to experience steady growth as excessive bleeding during surgical procedures has increased in occurrence. Antithrombin deficiency can lead to thromboembolism, a condition in which a clot develops in a blood vessel, breaks loose from it, and is carried by the blood stream to another vessel. This can severely affect the functioning of other organs like kidneys, brain, gastrointestinal tract, and lungs. This can create complications during and after surgeries. The market potential of antithrombins is anticipated to significantly rise on the basis of these factors. Furthermore, the global antithrombin market is expected to gain considerable momentum during the forecast period on account of growing instances of hereditary antithrombin deficiency.

Side effects such as sores, blisters or ulcers in mouth is likely to hinder the market growth

On the contrary, the increased use of biologics and the high cost of antithrombin are the two factors constraining the growth of the market.

COVID-19 Impact Analysis

COVID‐19 is a highly prothrombotic disease, frequently requiring anticoagulation for prevention or treatment of thrombosis and to enable organ support.The reported incidence of thrombosis in patients with COVID‐19 varies considerably depending on anticoagulant regimen, severity of disease and additional risk factors such as central lines. Thus the person suffering from disease is a high chance to be suffered from the COVID-19.

Segment Analysis

Therapeutics, segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)   

Antithrombin can be used as therapeutics in conditions like cardiac surgeries, and in genetic condition like Antithrombin Deficiency. As per the data published by the American Society of Hematology 900,000 people in the United States develop blood clots yearly, and they are accountable for approximately 100,000 casualties each year. Furthermore, according to the National Organisation for Rare Disorders, every one person in 3000 to 5000 people in the United States has Type I antithrombin deficiency. The increasing prevalence of blood clotting diseases increases the therapeutics and diagnostic usage of Antithrombin.

Therapeutic drug pipeline or advancements in drug administering technology is also expected to fuel growth of antithrombin market. For instance, Fitusiran (ALN-AT3), developed by Alnylam Pharmaceuticals, Inc., is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT). This therapeutic that can be used for the treatment of hemophilia and rare bleeding disorders (RBDs) is in late stage (Phase 2-phase 3) clinical trial. Moreover, GTC Biotherapeutics, Inc.’s product called as ATryn Antithrombin (Recombinant), derived from human blood donors, is used for hereditary antithrombin deficiency and it recently got market approval in the U.S., thereby significantly contributing to the growth of antithrombin market. Therefore, introduction of new types of antithrombin products with different indication over the forecast period is expected to fuel growth of the global antithrombin market.


Source: DataM Intelligence Analysis (2020)

Geographical Analysis

Asia-pacific region holds the largest market share global antithrombin market  

The Asia-pacific region is expected to show a high growth due to the developing nations such as India and China that are embracing new treatment procedures and techniques to combat various diseases. The increase in non-refundable incomes developing countries and their increasing capability to invest more money for advanced healthcare creates more opportunities for the market in the Asia Pacific. Although the occurrence of venous thromboembolism (VTE) in Asian populations is lesser than in Western countries, the total burden of VTE in Asia has been substantially underestimated. Factors that may explain the lower prevalence of VTE in Asian populations relative to Western populations comprise the incomplete availability of epidemiological data in Asia, ethnic differences in the genetic predilection to VTE, underdiagnoses, low awareness toward thrombotic disease, and possibly less symptomatic VTE in Asian patients. In recent years the awareness of the disease is increasing, raising the need for diagnosis and treatment.

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

The antithrombin market is moderately competitive with presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, and Lee Biosolutions Inc., BDI Pharma among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antithrombin market globally.     

Thermo Fisher Scientific Inc. 

Overview: Thermo Fisher Scientific Inc., incorporated on October 11, 1960, develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Product Portfolio: The Company’s portfolio comprised of technologies for mass spectrometry, chromatography, elemental analysis, molecular spectroscopy, sample preparation, informatics, chemical research and analysis, cell culture, bioprocess production, cellular, protein and molecular biology research, allergy testing, drugs-of-abuse testing, therapeutic drug monitoring testing, microbiology, as well as environmental monitoring and process control.  

Why Purchase the Report?

  • Visualize the composition of the antithrombin market segmentation usage, source, route of administration, type and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in antithrombin market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of antithrombin market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global antithrombin market report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!